EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005

Annelies Wilder-Smith

Journal of Clinical Investigation · 01.02.2024 · 134 (3)

DOI: 10.1172/jci177610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.02.2024. Verfasst von Annelies Wilder-Smith. Hauptthemen laut MEDLINE: Dengue, Dengue Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue fever, caused by four distinct serotypes of the dengue virus (DENV1-4), poses a public health concern for much of the world. The NIH's Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) has developed a series of single-dose, live-attenuated tetravalent DENV vaccines, including TV005. However, phase III trials require a lengthy three-to-five year follow-up. In contrast, controlled human infection models (CHIMs) offer a faster means to assess vaccine efficacy for any of the four serotypes. In this issue of the JCI, Pierce, Durbin, and colleagues conducted a CHIM study with attenuated DENV2 and DENV3 challenge viruses in individuals six months after vaccination with TV005. The TV005 vaccine was well tolerated and effectively protected all vaccinated individuals from viremia and rash during challenges with DENV2 or DENV3. Notably, vaccine recipients also showed serotype-specific efficacy. While long-term studies are still needed, these findings represent an important step in providing protection against dengue virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DengueDengue VaccinesHumansAntibodies, NeutralizingAntibodies, ViralDengue VirusVaccinationVaccines, AttenuatedClinical Trials, Phase III as Topic

Substanzen

Antibodies, NeutralizingAntibodies, ViralDengue VaccinesVaccines, Attenuated

Zitieren

APA

Wilder-Smith, A. (2024). Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005. Journal of Clinical Investigation, 134(3). https://doi.org/10.1172/jci177610

Vancouver

Wilder-Smith A. Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005. Journal of Clinical Investigation. 2024;134(3). doi:10.1172/jci177610

BibTeX
@article{WilderSmith2024,
  author = {Wilder-Smith, Annelies},
  title = {Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {3},
  doi = {10.1172/jci177610}
}
Kostenlos starten →